Pipeline
One platform. Six active programs. One vaccine already in a confirmatory trial.
SurVaxM is validated first in glioblastoma and already moving into four more indications. Behind it, three earlier-stage programs extend the same survivin target into antibody and cell-therapy formats.
Lead asset
SurVaxM® — cancer vaccine
A survivin-targeting peptide-mimic vaccine, in clinical development across six indications from a single confirmed mechanism.
FDA designations already granted
Clinical — SurVaxM
SURVIVE has completed enrollment. For currently enrolled patients, and others asking about SurVaxM outside of a trial, see our Expanded Access Policy.
Discovery & pre-clinical — beyond the vaccine
MV2C2 is supported in part by the NIH National Institute of Neurological Disorders and Stroke (NINDS).
Enrolling now
See which SurVaxM studies are open near you.
Full listings, eligibility criteria and sites are maintained on ClinicalTrials.gov rather than duplicated here, so the record always matches the official one.